India, Aug. 4 -- Praxis Precision Medicines, Inc. (PRAX), a clinical-stage biopharmaceutical company, Monday announced positive topline results from the Phase 2 RADIANT study evaluating vormatrigine in patients with focal onset seizures. Following the news, the company's shares were more than 20% up in pre-market trading.
Results from the study showed that treatment with vormatrigine for more than 8 weeks led to 56.3% median reduction in seizure frequency, with nearly 22% of patients achieving 100% reduction in the last 28 days. Further, more than 54% of patients achieved 50% response in the first week. The drug candidate was generally well tolerated with a favorable safety profile.
Additional data will be presented at the 36th Internatio...